Association of chronic anticoagulant and antiplatelet use on disease severity in SARS-COV-2 infected patients

J Thromb Thrombolysis. 2021 Aug;52(2):476-481. doi: 10.1007/s11239-021-02383-w. Epub 2021 Feb 1.

Authors

Gwendolyn Ho¹, Jennifer R Dusendang², Julie Schmittdiel², Juraj Kavecansky³, Jahan Tavakoli⁴, Ashok Pai⁵

Affiliations

¹ Department of Hematology Oncology, The Permanente Medical Group, Kaiser Permanente, Sacramento, CA, USA. Gwendolyn.h.ho@kp.org.
² Division of Research, Kaiser Permanente, Oakland, CA, USA.
³ The Permanente Medical Group, Kaiser Permanente, Walnut Creek, CA, USA.
⁴ The Permanente Medical Group, Kaiser Permanente, San Francisco, CA, USA.
⁵ The Permanente Medical Group, Kaiser Permanente, Oakland/Richmond, CA, USA.

No abstract available

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Anticoagulants / adverse effects
Anticoagulants / therapeutic use*
COVID-19 / diagnosis*
COVID-19 / mortality
COVID-19 / therapy
California / epidemiology
Comorbidity
Female
Hospitalization
Humans
Male
Middle Aged
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / therapeutic use*
Respiration, Artificial
Retrospective Studies
Risk Assessment
Risk Factors
Severity of Illness Index
Venous Thromboembolism / epidemiology
Young Adult

Substances

Anticoagulants
Platelet Aggregation Inhibitors